Dynavax Technologies
2100 Powell Street
Suite 300
Emeryville
California
94608
United States
Tel: 510-848-5100
Fax: 510-848-1379
Website: http://www.dynavax.com/
Email: contact@dynavax.com
About Dynavax Technologies
We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.
463 articles about Dynavax Technologies
-
Asthma drug failed to show a statistically clinical improvement in controlling asthma, Dynavax said.
-
Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.
-
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Feb. 5, 2018
2/5/2018
These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
-
Dynavax Technologies Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
1/15/2018
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $16.85 per share.
-
Dynavax Announces HEPLISAV-B is Now Available in the United States for the Prevention of Hepatitis B in Adults
1/8/2018
HEPLISAV-B can now be ordered through a network of distributors, which will broaden over the next few weeks.
-
Dynavax Technologies Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/6/2017
Dynavax granted stock options to purchase shares of Dynavax's common stock to the new employees with an exercise price of $18.40 per share.
-
The FDA approved Dynavax's Heplisav-B, it's first new hepatitis B vaccine in the U.S. in more than 25 years.
-
Dynavax Reports Third Quarter 2017 Financial Results
11/3/2017
Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at December 31, 2016.
-
Here's a closer look at six drugs facing FDA decisions in November.
-
Dynavax Initiates Clinical Trial In Non-Small Cell Lung Cancer With A Novel Inhaled TLR9 Agonist In Combination With Anti-PD-1 Therapy
10/19/2017
Dynavax Technologies Corporation announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC).
-
Bay Area's Dynavax Quietly Shops Around Its Almost-Approved Hep B Vaccine
10/3/2017
-
Dynavax To Present At Upcoming Investor Conferences
9/5/2017
-
Dynavax Announces Exercise In Full Of Over-Allotment Option And Completion Of Public Offering Of Common Stock
8/16/2017
-
Dynavax Announces Proposed Public Offering Of Common Stock
8/9/2017
-
Dynavax Shares Plunge on Delayed FDA Decision for Hep B Vaccine Heplisav
8/4/2017
-
Dynavax Reports Second Quarter 2017 Financial Results
8/2/2017
-
FDA Panel Votes to Recommend Dynavax's Hepatitis B Vaccine; Hepsilav Can Compete With GlaxoSmithKline's Engerix-B
7/31/2017
-
Death Count Rises for Patients on Dynavax's Hep B Vaccine But Overall Rate Was Low, Says the FDA
7/27/2017
-
Dynavax To Present Data On SD-101 In Combination With KEYTRUDA At The 2017 ASCO Annual Meeting
5/19/2017
-
Dynavax Reports First Quarter 2017 Financial Results
5/8/2017